MIAMI, FLORIDA (STRICTLY EMBARGOED UNTIL DEC. 8, 2024, AT 12 NOON EST) – Two clinical trials testing the antibody loncastuximab tesirine (Zynlonta) showed encouraging results in patients with ...
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) today announced that the Company will present new data from across its oncology portfolio at the 2024 American Society of Hematology (ASH) ...
The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival (PFS) and key secondary endpoints in patients with relapsed or refractory follicular lymphoma (FL) treated with ...
Epkinly, combined with Revlimid and Rituxan, shows improved progression-free survival and response rates in relapsed or refractory follicular lymphoma. The EPCORE FL-1 trial demonstrated a 79% ...
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (ADCT) today announced that initial data from an investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA® ...
A Phase I trial involving ten patients with relapsed or refractory classical Hodgkin lymphoma or T-cell lymphoma has achieved a 100% overall response rate and a 50% complete remission rate, in ...
HOUSTON -- Already indicated for relapsed/refractory follicular lymphoma, the bispecific antibody mosunetuzumab (Lunsumio) showed early promise for improving outcomes in two key lymphoma subtypes, ...
ORLANDO, Fla. — Adding epcoritamab (Epkinly) to the standard-of-care (SOC) therapy of lenalidomide (Revlimid) and rituximab (Rituxan), a combination known as R 2, lowered the risk for disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results